Sanofi
Sanofi appoints Paul Chew as chief medical officer
October 1, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Paul Chew, Sanofi
Sanofi has appointed Dr Paul Chew as chief medical officer and head of global medical affairs. Taking up his post …
Sanofi to cut 900 jobs in France
September 26, 2012Research and Development Jobs, Sanofi, pharma job cuts, restructuring
Sanofi is to cut 900 jobs in its French operations by 2015 – fewer than expected after widespread speculation this …
Pharma creates non-profit R&D organisation
September 21, 2012Research and Development, Sales and Marketing Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Co, GlaxoSmithKline, Johnson & Johnson, Pfizer, R&D, Roche Genentech, Sanofi, TransCelerate BioPharma, biopharma
Ten biopharma companies have formed TransCelerate BioPharma Inc, a not-for-profit organisation using money and personnel from each firm, with a …
Sanofi cleared in sales row
September 20, 2012Medical Communications, Sales and Marketing ABPI, CDF, Jevtana, PMCPA, Sanofi
Sanofi has been cleared of any wrongdoing after allegations that it had broken multiple clauses in the ABPI Code of …
Setback for Sanofi dengue vaccine
September 13, 2012Research and Development, Sales and Marketing Dengue fever, Sanofi, Sanofi Pasteur, Vaccine
Sanofi Pasteur’s vaccine for dengue fever has failed to show protection against a key serotype of the potentially fatal illness. …
Genzyme MS drug approved in US
September 13, 2012Medical Communications Aubagio, Genzyme, Rebif, Sanofi, Tysabri, gilenya, multiple sclerosis
US regulators have given the green light for Genzyme’s Aubagio to treat patients with relapsing forms of multiple sclerosis (MS). …
Sanofi’s colorectal cancer drug gains FDA approval
August 6, 2012Sales and Marketing FDA, Sanofi, Zaltrap, colorectal cancer
The FDA has approved Sanofi and Regeneron’s new oncology drug Zaltrap for aggressive forms of colorectal cancer.Zaltrap (ziv-aflibercept), in combination …
Negative overtures persuade Sanofi to withdraw drug filing
July 10, 2012Sales and Marketing EMA, Mulsevo, Sanofi, blood clots, withdrawal
Sanofi has withdrawn its marketing applications worldwide for its drug Mulsevo. Designed to stop blood clots in cancer patients receiving …
More job cuts planned at Sanofi, says union
July 6, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Genzyme, Sanofi, Viehbacher, cuts
Sanofi has confirmed that it is considering a restructuring of its operations in France, but has refused to comment on …
Positive data for Sanofi’s diabetes drug
June 13, 2012Research and Development, Sales and Marketing Lyxumia, Novo Nordisk, Sanofi, Victoza, diabetes
Sanofi’s new diabetes treatment Lyxumia has significantly reduced glycated hemoglobin (HbA1c) in two late-stage trials, the manufacturer says. Paris-based Sanofi …
Sanofi submits key MS pill for approval
June 12, 2012Research and Development, Sales and Marketing Bayer, EMA, FDA, Genzyme, Lemtrada, MS, Sanofi
Sanofi has submitted its multiple sclerosis pill Lemtrada for regulatory reviews in the US and Europe. Lemtrada (alemtuzumab), originally developed …
Sanofi/Regeneron cholesterol drug reaches Phase III
May 29, 2012Research and Development, Sales and Marketing Amgen, PCKS9, Regeneron, SAR236553, Sanofi
Sanofi and Regeneron’s anti-cholesterol drug has impressed in a mid-stage trial, and will now progress into Phase III. The firms’ …
Public-private alliance to discover new antibiotics
May 25, 2012AstraZeneca, EFPIA, GSK, Janssen, Sanofi, antibiotic, bacterial infection
A Europe-wide public-private partnership is to put €224m (£180m) into finding new antibiotics for all manner of bacterial infections such …
Plavix loses US patent protection
May 18, 2012Sales and Marketing BMS, FDA, Lipitor, Pfizer, Plavix, Sanofi
Sanofi and Bristol-Myers Squibb’s blood thinner Plavix has lost its patent protection in the US. The drug, which made $6.6 …
Genzyme boosts capacity following green light for Waterford plant
May 8, 2012Manufacturing and Production EMA, FDA, Genzyme, Sanofi, Waterford
Sanofi subsidiary Genzyme has doubled its capacity to fill-and-finish two of its drugs for rare disorders following approval of a …
Latest content
Five Facts about cardiovascular disease
